HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beauty Launch News: Celeb Scents, 'Clean' Baby Care, Female Hair-Loss Products And ... Flip-Flops?

Executive Summary

From Revlon’s latest celeb fragrances to OPI-inspired flip-flops, beauty launch news.

You may also be interested in...



Revlon Watching For Color Cosmetics Rebound In 2021

The New York-based firm reported net sales declines of roughly 10% and 21% for the fiscal 2020 fourth quarter and full year, with COVID-related impacts on color cosmetics weighing heavily on its namesake and Portfolio businesses.

Coty Prepared For Possibility That COVID-19 Revenue Recovery Could Be Years Away

The beauty giant says it is selling its Professional Beauty and retail hair-care businesses to global investment firm KKR and targeting $700m in cost reductions over the next two and a half years. Coty already was in transformation mode prior to COVID-19, which drove a 23% decline in its third-quarter net sales, and it does not expect revenue levels to normalize anytime soon.

P&G’s NIOXIN Shows How To Address Hair Loss Without An FDA Warning

With FDA scrutinizing the marketplace for cosmetics promoted as drugs, and a clear cautionary statement from the agency about topical products marketed as hair growers or hair-loss preventers, beauty firms have little choice but to incorporate approved OTC drug ingredients in such products. P&G’s professional hair-care brand NIOXIN has done just that with its new Advanced Thinning range featuring minoxidil.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel